Información:
Error:
ID
14001
Descripción
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient; ODM derived from: https://clinicaltrials.gov/show/NCT01766375
Link
https://clinicaltrials.gov/show/NCT01766375
Palabras clave
Versiones (1)
- 21/3/16 21/3/16 -
Subido en
21 de marzo de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Acute Myeloid Leukemia NCT01766375
Eligibility Acute Myeloid Leukemia NCT01766375
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01766375
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Age
Item
Age: 18～50
boolean
C0001779 (UMLS CUI [1])
Peripheral Stem Cell Transplantation
Item
Received peripheral blood hematopoietic stem cell transplantation from siblings or unrelated allogeneic donors with identical matching of hla or 1 alleles mismatched.
boolean
C0242602 (UMLS CUI [1])
Acute Erythroblastic Leukemia
Item
Diagnosis: refer to 2011 edition of aml china guideline for the diagnosis and treatment and diagnosis standards of high-risk acute myeloid leukemia developed through literatures (see appendix b);
boolean
C0023440 (UMLS CUI [1])
ECOG performance status
Item
Under general condition, ecog score ≤ 1;
boolean
C1520224 (UMLS CUI [1])
Cardiac function
Item
Normal cardiac functions
boolean
Renal and Liver function
Item
Normal liver and renal function: blood bilirubin≤35 μ mol\/l, ast/alt lower than twice in the upper limit of normal value, serum creatinine≤ 150 μ mol\/l;
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232804 (UMLS CUI [2])
Informed consent
Item
Subjects have signed the informed consent form.
boolean
C0021430 (UMLS CUI [1])
Infection
Item
Severe uncontrolled infection before transplantation;
boolean
C3714514 (UMLS CUI [1])
Idarubicin
Item
With contraindications of idarubicin
boolean
C0020789 (UMLS CUI [1])
Anthracycline Antibiotics
Item
Reached the maximum cumulative dose of anthracyclines, for instance, dnr≥ 450mg/m2, mitoxantrone≥140mg/m2, the total cumulative dose of idarubicin≥ 300mg/m2;
boolean
C0003234 (UMLS CUI [1])
Inclusion criteria
Item
The other conditions that do not meet the inclusion criteria.
boolean
C2827031 (UMLS CUI [1])
CL Item
Those do not meet the inclusion criteria or meet the exclusion criteria after reviewing (1)
C2827031 (UMLS CUI-1)
CL Item
Patient withdraws the informed consent form (2)
C0021430 (UMLS CUI-1)
CL Item
Patient violates the clinical study protocol (3)
C2348563 (UMLS CUI-1)
CL Item
Patient experiences severe adverse events that treatment has to be terminated (4)
C0877248 (UMLS CUI-1)
CL Item
Patient that considered no longer fit to complete clinical trials by researchers. (5)
C0525058 (UMLS CUI-1)